GraniteShares 2x Long COIN Daily ETF vs Halozyme Therapeutics Inc. Common Stock — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.35 (market cap $510.01M), while Halozyme Therapeutics Inc. Common Stock trades at $111.12 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 24.7× GraniteShares 2x Long COIN Daily ETF's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| CONL | HALO | |
|---|---|---|
Market Cap | $510.01M | $12.58B |
Volume | 21,041,836 | 2,179,278 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $115.22 |
52-Week Low | $3.93 | $61.63 |
Typical Hold Time | 15 Days | 1 Days |
Enterprise Value | — | $14.49B |
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $5.41, up 3.44% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF, which provides 2x daily leveraged exposure to Coinbase Global stock, faces volatility from its underlying asset's performance. Recent news highlights significant price gaps and volume spikes, with the stock previously gapping up to $6.44 on October 1, 2026.
The outlook remains high-risk due to leveraged structure amplifying Coinbase's volatility. Investment opportunity exists for short-term traders betting on Coinbase rebounds, but risks include rapid decay from daily rebalancing and crypto market downturns. Long-term holders face erosion from volatility drag, requiring careful risk management.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →